Use of glucagon-like peptide-1 (GLP-1) medications for weight loss has surged among adults in the United States, rising from 3% in 2024 to 11% in the past two years, according to a new report cited by EPIC Research.
Rapid uptake and what it means
The figures suggest nearly 9,000 per 100,000 patients in the U.S. are now on GLP-1 prescriptions such as Wegovy and Ozempic. Health-care providers and patients say the drugs can be effective components of weight-management plans, but they are not a standalone solution and do not replace long-term lifestyle change.
Clinicians emphasize that obesity is a chronic condition that requires sustained attention to diet, activity and follow-up care. At the same time, many patients report transformative results that have reshaped their relationship with food and exercise.
Patient experience and clinical perspective
A working mother featured in the report described decades of diligent exercise and persistent weight struggles before starting a GLP-1 medicine through a structured weight-loss program. She said the medication helped reduce constant thoughts about food and enabled meaningful weight loss while she maintained an active routine.
“GLP-1 really quieted the food noise, which was always a problem,” the patient said. “Back before I started a GLP-1, it didn't matter. I would have a meal and then I would immediately begin thinking about what I was going to eat next.”
Providers cited in the report note typical weight loss ranges for some patients of roughly 15% to 19% while taking certain GLP-1 medications. They also warn that stopping therapy often results in partial weight regain — with some patients regaining about 60% of lost weight within the first year after discontinuation.
- 2024 vs. now: National use rose from 3% to 11% among adults.
- Prevalence: Approximately 9,000 users per 100,000 people in the U.S.
- Outcomes: Many patients report 15%–19% weight loss; stopping medication often leads to weight regain.
Context and consequences
The rapid adoption of GLP-1 drugs has implications for clinicians, insurers and patients. Increased demand may affect medication access and costs, while the need for integrated care — combining pharmacotherapy with nutrition counseling, physical activity and behavioral support — becomes more pronounced. Providers stress that medication should be part of a comprehensive plan rather than a quick fix.
For people considering GLP-1 therapy, programs that offer medical oversight and follow-up can help manage expectations and reduce the risk of rebound weight gain. The patient account in the report highlights the value of combining medication with continued exercise and diet changes under professional guidance.
| Metric | Value |
|---|---|
| Adult use (2024) | 3% |
| Adult use (current) | 11% |
| Users per 100,000 | ~9,000 |
The trend reflects changing approaches to managing obesity in the U.S. and underscores the urgency for public discussion about long-term treatment strategies, equitable access and what sustained care looks like for patients who start these medications.
